BCL2 and non-small cell lung carcinoma: Preclinical studies have shown that Oblimersen sodium reduces Bcl-2 expression, leading to cytotoxic and cytostatic effects in various cancer cells, including breast, ovarian, prostate, melanoma, non-small-cell lung carcinoma (NSCLC), bladder, and gastric cancers [198,199,200,201,202,203,204].